Key Takeaways
- Ascribe Bio has entered a strategic multi-year research and development collaboration with Corteva.
- The partnership will evaluate the use of ascaroside technology for seed treatment applications to protect seedlings from early-season fungal diseases.
- The technology, currently marketed as Phytalix®, utilizes natural small molecules to prime plant resistance pathways.
- This initiative targets the global seed treatment market, which is projected to reach approximately $11 billion by 2030.
- The collaboration aims to provide farmers with new, sustainable tools for targeted disease control and improved root development.
Ascribe Bio Collaborates with Corteva on Biofungicide Technology
Ascribe Bio has announced a strategic research and development collaboration with Corteva to advance its novel biofungicide technology for seed treatment applications. This multi-year project focuses on evaluating how ascaroside technology can protect germinating seeds and young seedlings from early-season fungal diseases. While the technology is currently being commercialized in Phytalix® products for foliar applications, this new research explores its potential as a targeted seed-applied solution.
The global seed treatment market is experiencing significant growth, driven by demand for tools that support sustainable farming practices and protect crop yields. By applying biofungicides directly to the seed, the partners aim to help crops withstand soil-borne pathogens and environmental stress during the critical early stages of growth.
Expanding Ascribe Bio Research into Seed-Applied Solutions
The expansion into seed treatments represents a significant milestone for the company's product pipeline. “Our research now shows that the same non-toxic mode of action can also benefit crops when applied as a seed treatment, and this collaboration will allow us to develop that potential at scale with a global leader in seeds and seed care,” said Jay Farmer, CEO of Ascribe Bio.
